i
Curriculum Vitae
Dr Paul Witting
ANZAC Research Institute
ii
Executive Summary: Dr Paul Witting is a career biomedical researcher. He has held ARC (20032007) and National Heart Foundation Fellowships (1999-2001) that financed post-doctoral terms at the
ANZAC Research Institute and University of British Columbia (Canada), respectively. He has a proven
track record in the field of bio-medical chemistry. Witting has published 57 peer-reviewed papers
(average impact factor (IF) ~4.6 with >90% appearing in international journals); 4-book chapters; 8invited review articles and one International Patent [W95]. Notably, 2 papers have been selected as
journal covers [W3 - IF 3.6; W73 - IF 3.5]; 10 have appeared in the Journal of Biological Chemistry; 8
have appeared in American Chemical Society Journals; 2 others [W21 - IF 14.3; W47 - IF 14.6] have
attracted editorial comments and others [W24 - IF 6.8, W39 - IF 11.2] appear in the AHA journals
Arteriosclerosis, Thrombosis and Vascular Biology and Circulation. A year-by-year distribution of peerreviewed publications is shown in Fig. 1. Witting is first or senior author in ~62% of his publications
and his work has been acknowledged with 1301 citations in total (average citation per publication ~23
yielding an H-index ~23). He has been awarded ~A$3.4 Million in competitive funding from agencies
including the ARC, NHF, Wellcome Trust, NHMRC Equipment Grants, The Ramaciotti, Bushell and
CASS Foundations, Eli Lilly Diabetes Foundation, Diabetes Australia Research Trust and the
University of Sydney Strategic Development Grants Scheme.
8
3/4
7
2/3
6
Mean IF
3/5 4/7
5
4/6 1/4
4
3
4/6
0/2
3/6
2/3
4/6
2/3
3/3
2/3
2
1
Figure 1.
Year-by-year breakdown of peer-reviewed
publications for Dr Witting. Annotated numbers appearing
above the individual columns (A/B) represent A - the number
of first or senior author contributions in the year indicated over
B - the total number of publications for the indicated year.
Overall, Witting has a career (average) publication rate of 4.3
papers per annum with an average impact of ~4.6 (dashed
line) based on all publications and using the 2006 impact
factor values cited in the Web of Science.
0
95
96 97
98
99 00
01
02
03 04
05
06 07
08
Year
Research training commitments. Witting has successfully completed the University of Sydney
Institute of Teaching and Learning (on-line) course. He has attended the Orientation for New
Supervisors/managers Course (University of Sydney Staff Support and Development Unit) and the
ChemAlert Departmental Training Lectures (Concord Hospital OH&S Department). As a result he is
now registered on the University of Sydney Faculty of Medicine Supervisor list and acts as a primary
supervisor for PhD candidates. Since moving to the ANZAC Research Institute, he has been involved
in lecturing to undergraduate students in the Pathology Department (University of Sydney) and has
been a guest lecturer for a series of two-day seminars for 3rd year students as part of the Molecular
Medicine Syllabus (Griffith University, Gold Coast). Witting currently manages the Vascular Biology
Group of 17 researchers with a yearly consumable budget of over $110K. He employs two postdoctoral scientists and supervises four post-graduate students (two funded by competitive National
Heart Foundation (NHF) and Philip Bushell Foundation PHD scholarships), one research assistant and
one honours student (2008). Additionally, Witting has supervised seven undergraduate students
(funded competitively by University of Sydney Medical Faculty and NHF Summer Vacation
Scholarships–his Summer student for 2008 was selected to represent the ANZAC Research Institute
at the Dean’s Honour Award) and three Honours graduates (outcomes 2005: H2-1; 2006: H1; 2007
H2-1). A summary of his supervisory roles is shown in Table 1 (below).
Significant contributions to science. Witting received his doctorate in 1994 graduating from the
School of Chemistry (University of Sydney) where he specialised in redox chemistry with an emphasis
on quantitative analytical assays including HPLC, electrochemistry, mass spectrometry and electron
paramagnetic resonance spectroscopy and published 6 papers. Next, he completed a successful
post-doctoral appointment with Prof. Roland Stocker (1994-1999) at The Heart Research Institute (HRI,
Sydney) publishing 16 research papers exploring the impact of oxidative stress in biological systems.
He then spent two years with Prof. Grant Mauk (UBC) studying the peroxidase activity of recombinant
wild-type and site-directed variants of human myoglobin with a trilogy of ground-breaking publications
appearing in the Journal of Biological Chemistry. On his return to Sydney, he worked at the HRI (Feb
iii
2001), then moved with Prof. Stocker (April 2002) to the Centre for Vascular Research (UNSW) where
he was instrumental in re-establishing Stocker’s laboratory and providing research impetus to facilitate
the implementation of Stocker’s research. Key achievements from this period include: (a) developing
and Patenting (W94) a method for detecting inhibitors of lipid oxidation; (b) Screening and identifying
novel antioxidants with this method [W4 - IF 3.9], and (c) testing key inhibitors in animal intervention
studies (commercial project with AstraZeneca). Lead compounds identified by the screening assay
inhibit the accumulation of toxic aortic lipid hydroperoxides providing proof of concept [W19- IF 7.1;
W21 - IF 14.3]. Commercial groups have commissioned the “Screening assay” eg., Blackmores (Aus),
Actelion Ltd (Switzerland), Chugai Pharmaceuticals Ltd (Japan) and Novogen (Aus).
In August 2003, Witting accepted a position at the ANZAC Research Institute (Concord Repatriation
General Hospital; CRGH) with a goal to establish an independent Vascular Biology Group. To achieve
this, he has gained over A$380K in equipment grants. This relocation has facilitated interactions with
Clinicians (Cardiology and Neuroscience Departments, CRGH) and focussed his research on
exploring a role for oxidative stress in myocardial dysfunction. For example, he has established an
assay to identify the biological “footprint” of lipid oxidation promoted by human myoglobin [W38 – IF
4.1] that will verify a role for this protein in myocardial injury. Additionally, he has been instrumental in
establishing and validating animal models of in situ myocardial infarct [W68] and cerebral ischemia.
More recently, his research interests have broadened to include cerebral stroke and the affects of
ischemia reperfusion injury in promoting neuronal cell dysfunction [W46].
Editorial responsibilities. Witting reviews manuscripts (1-2 p.a.) from: Journal of Biological
Chemistry, Brain Research Bulletin, Biochemistry, FEBS Letters, Journal of Pharmacology and
Experimental Therapy, Biochimica Biophysica Acta, Future Medicine, Chemistry Euro. Journal, J. Lipid
Research, Free Radials in Biology and Medicine, Clinical and Experimental Pharmacology and
Physiology, Chemical Research and Toxicology and regularly reviews (3-5 p.a.) submissions to Redox
Report, Journal of Neurochemistry, Sleep and Free Radical Research. He assesses ARC, NHMRC
and NHF (Grant-in-aid and Fellowship) applications and has assessed New Zealand HRC and
Neurological Foundation applications. He has been a guest Editor for the journal Redox Report and
state-of-the-art reviews for the 2005 proceedings of the International Society for Thrombosis and
Haemostasis (ISTH). Witting was the Secretary for the Society for Free Radical Research
(Australasia) [SFRR(A)] for 6 consecutive years and was part of the organising committee for two
national SFRR(A) (Melbourne 1998 and Wollongong 2002) and one international (inaugural SFFR(A)
and SFRR(Japan) (Sydney 2001)) meetings. He was a member of the Executive Committee for the
Australian Vascular Biology Society (AVBS, 2005) and was invited to present a seminar at a Satellite
meeting of the ISTH (Sydney 2005). He was the chairperson of the Organising Committee for the
highly successful ANZAC Annual One-day Symposium (2006) that accumulated a budget of ~$26,000
and brought together ~ 80 researchers with a common interest in ischemia reperfusion damage to the
tissues of the heart and brain.
Invited presentations. Witting has delivered invited seminars at international SFRR meetings (Spain
1996; Sao Paulo 1998 and Kyoto 2003 and 2007) and the 10th International Sleep and Breathing
Meeting (Cairns, 2007) and the International Meeting of Sleeping Disorders (World Sleep 2007,
Cairns). He has also been invited to present at national meetings of the Australian Atherosclerosis
Society (Leura 1997, Sydney 2002), Australian Society for Clinical Biochemists (Brisbane 1998),
Australian Health and Medical Research Congress (Sydney, 2004), Australian Vascular Biology
Meeting as a satellite for the ISTH Meeting (Sydney, 2005).
Table 1. SUPERVISION OF HIGHER DEGREE CANDIDATES
Mastersa
Honours
a
PHDb
Vacation Scholarshipc
Completedd
Current
Completed
Current
Completed
Current
Completed
Current
3
1
2
0
0
3
8
0
One student co-supervised with Professor Ben Freedman, Department of Cardiology, Concord Hospital. Another completed
a Masters by course work and fulfilled the research component under the supervision of Dr Witting.
b One student co-supervised with Dr Qihan Dong, Senior Lecturer Endocrinology, University of Sydney. Two of three PHD
students are funded by competitive scholarships from the NHF and Bushell Foundations, the other has an International
Scholarship (from Iran).
iv
c
d
Students funded by competitive Vacation Scholarships from the University of Sydney and NHF schemes .
Students completing Honours have achieved H2-1 (2005), H1 (2006) and H2-1 (2007).
v
Curriculum Vitae
______________________________________________________
Name:
Paul Kenneth Witting
Marital status:
Married
Current Address:
Senior Scientist,
Date of Birth: 15th of September, 1967
Citizenship: Australian
Vascular Biology Group,
The Anzac Research Institute,
Hospital Road, Concord Repatriation General Hospital
Concord, NSW 2139
Current phone:
(02) 9767-9103
E-mail:
pwitting@anzac.edu.au
Facsimile:
(02) 9767-9101
Education:
Secondary — Higher School Certificate Aggregate (400); Mathematics, English, Physics, Chemistry,
Engineering science and General studies.
Tertiary — Bachelor of Science 1988, Honours (First Class) Organic Chemistry 1989 University of
Sydney, Doctorate of Philosophy (PHD) 1994, University of Sydney.
Technical Expertise:



Organic synthesis utilising a variety of preparative techniques,
Electrochemical analyses with a BAS100 electrochemical analyser,
Extensive analytical and preparative HPLC (normal and reversed-phase) employing a variety of
detection modes such as: oxidative and reductive amperometric electrochemical detection, UV-Vis,
RI, fluorescence and post-column chemiluminescence detection.

Electron paramagnetic resonance (ESP 300/300e and EMX bench-top spectrometers) operating at
temperatures ranging 293 to 4 K and nuclear magnetic resonance spectroscopy (200 Mhz and 90
Mhz),

Site-directed mutagenesis of DNA, DNA amplification using the polymerase-chain-reaction and
other molecular biology techniques associated with expression and purification of DNA and mRNA,





Expression and purification of recombinant proteins from bacterial and yeast cultures,
Measurement of cellular nitric oxide (NO) with a NO-selective electrode and EPR trapping agents,
Optical analyses including UV/Vis, FT-IR, CD and fluorescence spectroscopy,
Collection of venous whole blood from human donors,
Small animal surgery (ie., collection of whole blood by cardiac puncture and removal of tissues,
including the entire aortic tree, from mice and rabbits for biochemical and histological analyses),



Isolation of plasma and plasma lipoproteins by ultra-centrifugation and FPLC techniques,
Word processing using Microsoft Word, Excel, Scientist and Kaleidegraph,
Statistical analyses of data (Prism), and multi-media presentation (PowerPoint and Origin software).
______________________________________________________
vi
______________________________________________________
Grants Awarded:




















2008: Allan CM, Seibel M, Handelsman DJ, Witting PK, Kennerson M, Freedman SB, Cogger V,
Robertson G, Le Couteur D. NHMRC Equipment grant. Olympus Confocal Microscope Upgrade
($63.332K)
2008: University of Sydney DVC Research Bridging Support Scheme. Witting PK: Role for
Neuroglobin in protecting neuronal cells in models of cerebral inflammation ($50 K).
2008: University of Sydney Medical Faculty Strategic Grants Scheme. Witting PK: Investigation of
novel protein post-translation modifications in the infarcted heart ($50 K).
2008-2010: Australian Research Council Discovery Grant. Witting PK (DP0878559, $140 K p.a.):
Cellular response to pro-oxidative myoglobin.
2008-2009: NHF grant-in-aid. CI: Witting PK, Corbett AC, Brieger D. AI: Freedman SB and Kril J
(G 07S30435, $65 K p.a.): Developing a novel antioxidant that synergises with current
thrombolytic treatments for acute cerebral ischemia.
2008: Diabetes Australia Research Trust research grant. Witting PK: Synthetic polyphenol
antioxidants that reverse diabetes-induced vascular dysfunction ($50 K).
2008: Diabetes Australia Research Trust research grant. Lowe HC, McMahon AC, and Witting
PK: An examination of mechanisms of poor outcomes after heart attack in diabetes ($50 K).
2008: Diabetes Australia Research Trust research grant. McMahon AC, Witting PK & Lowe HC:
Evaluation of antioxidant treatment to reduce heart attack severity in diabetes (Type I) ($50 K).
2003-2007: Australian Research Council Fellowship, Witting PK (DP0343325, $151.9 K p.a.):
Biochemical properties of S-nitroso-myoglobin and its role in regulating nitric oxide bio-availability.
2007: Cancer Bequest Funding to Qihan Dong and Witting PK ($24 K)
2007: Witting PK, McMahon A, Lowe H, Dunstan C, Winlaw D, and Handelsman D. NHMRC
Equipment grant. Expanding the small animal surgery facility, ANZAC Research Institute ($14.1 K)
2007: Lay PA, Hunt NH, Grau ER, Sorrell TC and Witting PK. NHMRC Equipment grant. Twister
microplate handle: A robotic system for the Bruker HTS-XT infrared module ($81.52 K).
2006: Eli Lilly Diabetes Grant-in-aid, Witting PK and Thomas SR: Developing a model of diabetic
vascular dysfunction ($20 K)
2006: Philip Bushell Foundation Grant-in-aid, Witting PK ($19.3 K)
2006: Diabetes Australia Research Trust. Thomas SR and Witting PK: Oxidative mechanisms
that cause endothelial dysfunction ($50 K)
2006: Diabetes Australia Research Trust. Lowe HC, Kachigian L, Witting PK and McMahon AC:
Gene targeting to treat heart attack in type-2 diabetes ($50 K)
2004-2006: ARC Discovery Grant (DP0453372, $70 K p.a.). Neuzil J (Griffith University, QLD),
Witting PK (ANZAC Research Institute, NSW) and Salvatore BA (University of South Carolina,
USA): Novel vitamin E analogues with enhanced specificity for malignant cells.
2006: NHMRC Equipment Grant. OPMI Dissecting Microscope. Witting PK, Handelsman DJ,
Lowe HC, Le Couteur D, Muller M, Dunstan C, Winlaw DS, McMahon AC ($27.82 K)
2006: NHMRC Equipment Grant. Cell culture, quarantine and storage facility, awarded to
Dunstan C, Witting PK, Myers SJ, Handelsman DJ, Seibel M, Nicholson G, Zhou H, Kennerson
M, Allan C, Freedman SB, Le Couteur D, Muller M ($68.967 K)
2006: Ramaciotti Foundations Biomedical Research Award to Witting PK. Upgrading the Axiovert
200 fluorescence microscope ($25 K)
______________________________________________________
vii
______________________________________________________














2006-2008 Associate Investigator on ARC Discovery Grant DP0664706, Lay PA, Harris HH,
Stampfl AP ($342 K total) Nanoprobe and Microprobe Structural Studies in Biomedical Research.
2005: NHMRC Equipment Grant. Real-time PCR & Mutation detection system. Seibel M,
Nicholson GA, Handelsman DJ, Zhou H, Kennerson M, Dunstan C, Allan C, Witting PK, Kril J,
Freedman SB, Le Couteur D and Roberston G ($74.5 K)
2005-2007: Philip Bushell Foundation Grant-in-aid, Witting PK ($80 K PhD stipend).
2005-2007: NHF PHD Scholarship ($76 K awarded to Benjamin Rayner and Witting PK) Role for
extracellular myoglobin in promoting myocardial and vascular dysfunction.
2005: The CASS Foundation Ltd Grant-in-aid, Witting PK ($35 K).
2005: University of Sydney, Research and Development Grant, Witting PK & Brieger DJ ($38.9
K): Novel neutrophil function and neutrophil-derived fibrinolytic proteases in the plasminogendeficient mouse
2005: University of Sydney, Major Equipment Grant. VICTOR III Multi-label plate reader, Witting
PK, Lowe HC, Handelsman DJ, Le Couteur DM, Nicholson GA, Seibel M, Kril J, Kritharides L,
Kennerson M. ($45 K).
2004: Ramaciotti Foundations Biomedical Research, Purchase of a nitric oxide electrode. Witting
PK ($24.3 K).
2004: University of Sydney, College of Health Sciences Start-up Grant, Witting PK ($37.5 K).
2004: University of Sydney, Faculty of Medicine Start-up Grant, Witting PK ($37.5 K).
2004: NHMRC Equipment Grant. Bench-top ultracentrifuge. Witting PK, Lowe HC, Handelsman
DJ, Le Couteur D, Nicholson GA, Kril J, Kritharides L, Kennerson M, Harris M. ($75.3 K).
2003: Philip Bushell Foundation Small Equipment Grant, Witting PK ($17.5 K).
2002-2004: Wellcome Trust Large Equipment Grant ($530 K total) for the purchase of an L-band
electron paramagnetic spectrometer. Lay PA (USyd), Kennedy BJ (USyd), Witting PK (The Heart
Research Institute) and Davies MJ (The Heart Research Institute).
1999-2002: NHF Overseas Fellowship, Witting PK (O98S0008, 3 yrs, $65 K p.a.): Role for globinderived radicals in myocardial ischaemia reperfusion injury?
Funding and prizes to PKW or his students:








Concord Repatriation General Hospital Clinical Week Prize (2007) for outstanding research in
stroke awarded to Antao S. and Witting P.K. ($1000).
Australian Atherosclerosis Society Travel Grant and Best Poster Award (2007) to Antao S. and
Witting P.K. ($1000).
Honorarium to present at World Sleep 2007 awarded to Witting P.K. ($2000).
Concord Repatriation General Hospital Cardiology Travel Grant (2007) awarded to Witting P.K.
($4000) to attend The 13th World Congress on Heart Disease, Vancouver Canada.
Concord Repatriation General Hospital Clinical Week Prize (2006) for outstanding novel research
in Burns awarded to Parry S.N. and Witting P.K. ($500).
Society for Free Radical Research [SFRR] (Australasia) Young Investigator Award (2006) B.S.
Rayner, supervisor: Witting P.K. ($500).
Sydney University Medical Faculty Vacation Scholarships ($2 K per award) (2004) R. George and
P. Romo; (2005) Shane Antao and Sandra Wang; (2006) Shane Antao, Elicia Rodas (2007)
supervisor: P.K. Witting. Elicia Rodas was selected to represent the ANZAC Research Institute at
the 2007 Dean’s Honour Award.
Concord Repatriation General Hospital Clinical Week Prize (2004) for outstanding novel research
in stroke awarded to Rayner B.S. and Witting P.K. ($500).
viii
______________________________________________________
______________________________________________________











NHF Vacation Scholarship ($1.4 K) awarded to H. Duong. (Title: Role for extracellular myoglobin
in promoting myocardial and vascular dysfunction), supervisor: P.K. Witting, 2004.
The CASS Foundation Ltd Travel Grant ($1.6 K) awarded to P.K. Witting to attend FFFR2003
Kyoto Japan, December 2003
Philip Bushell Foundation Supplementary Travel Scholarship ($10 K p.a.), 1999-2001
Society for Free Radical Research [SFRR] (Australasia) Young Investigator Award ($2 K), 1998
International SFRR Travel Award ($500); 1998
National Heart Foundation travel award; 2000 (Oxygen Society Meeting, San Diego CA ($2 K)),
1996 and 1998 (International SFRR Meetings Barcelona and Sâo Paulo ($700))
University of Sydney George Harris Scholarship ($500) 1993 (continued excellence in research)
Australian Postgraduate Research Award ($14 K p.a.) 1990-1993
University of Sydney H. Bertie and F.M. Gritton (PHD) Scholarship ($2 K p.a.), 1992-1993
University of Sydney Edna May Goulston Award ($500) 1990 (outstanding Honours result)
University of Sydney Wesley College Academic Award 1989 ($500), 1990 ($500)
Previous Work Experience:
2001-2003: Centre for Vascular Research, University of New South Wales (UNSW) - After returning
from Canada I rejoined Professor Roland Stocker as a Senior Scientist initially at the Heart Research
Institute then at the Centre for Vascular Research, UNSW. Here I was instrumental in organising the
relocation of the Stocker lab including design of the new lab facilities at UNSW and recommissioning
of equipment. I also re-established research projects and trained new staff, particularly focusing on
animal intervention studies. Throughout, I maintained my own independece and in 2003 was awarded
a prestigious ARC Fellowship. Late in 2003, I transferred my Fellowship to the University of Sydney
and established the Vascular Biology Group, at the Anzac Research Institute (University of Sydney).
1999-2001: Biochemistry and Molecular Biology Dept, University of British Columbia, Vancouver - I
worked as an NHF funded Visiting Research Fellow (1999-2001) with Professor Grant Mauk studying
the biochemical characteristics of recombinant human myoglobin (rhMb). During this time I gained
expertise in site-directed mutagenesis and molecular biological techniques associated with DNA
manipulation. I also gained experience in the production and purification of recombinant proteins
through bacterial expression. My work with rhMb has led to the identification of a novel S-nitrosylated
form of the protein that may serve as a biologic sink for th epotent cell signalling molecule nitric oxide.
Additionally, work performed in Canada identified a series of potentially important bio-markers of rhMbinduced oxidative stress. Clinical studies with Prof. Ben Freedman, A/Profs Kritharides and Brieger
and Dr Lowe (Cardiology Department Concord Repatriation General Hospital) are addressing the
relevance of these myoglobin-derived bio-markers in patients suffering non-fatal myocardial infarct.
1994-1998: Biochemistry Group, The Heart Research Institute - I engaged in studies of human lowdensity lipoprotein (LDL) lipid (per)oxidation with Prof. Roland Stocker. During this time I established a
novel and rapid in vitro test to identify potent inhibitors (termed co-antioxidants) of LDL lipid
peroxidation. This research included screening a library of natural and synthetic antioxidants that has
led to the testing of several agents in animal models of atherosclerosis (e.g., Watanabe heritable
hyperliperdemic rabbits, apo-E-/- mice and apoE-/-;/LDL receptor-/- mice). These studies have led to
the international Patent of an active inhibitor of in vivo lipid oxidation.
ix
__________________________________________________
______________________________________________________
I have experience in collaborating with commercial groups (e.g., AstraZeneca and Actelion
Pharmaceuticals) and worked with a small-scale clinical trial (sponsored by Blackmores Australia)
investigating the effect of coenzyme Q10 on vascular tone (with Professor David Celemajer Royal
Prince Alfred Hospital).
1993-1994:
Research Assistant.
University of Sydney
Supervisor Dr Jill Greedy, Department of Biochemistry
Research Topic: Preparation and characterisation of inhibitors of the enzyme dehydrofolate reductase
(DFR). Here I was engaged in the synthesis of a series of analogues that
represented systematic changes in hydrophobicity.
These analogues were
demonstrated to be increasingly more potent inhibitors of DFR.
1989-1992:
Resident Chemistry Tutor at Wesley College, University of Sydney
1989-1992:
University of Sydney, practical class demonstrator
1990:
University of Technology Sydney, practical class demonstrator
1986-1987:
Part time sales assistant K-Mart Armidale, NSW.
Career/Staff Development:
(1)
Attendance at the Teaching and Learning Workshop, UNSW Career Development Course (April
2003).
(2)
Attendance at the Senior First Aid Certificate course (Valid 2003-2006).
(3)
Attendance at the Bio-safety and Infection Control training program run by the Risk Management
Unit at UNSW (October 2003).
(4)
Attendance at the Orientation for new supervisors/managers course (November 2004),
University of Sydney Staff Support and Development Unit.
(5)
Attendance at the SUPERVISOR WORKSHOP (CRGH) (March 2005) Lectures from Professor
Masud Behnia, Dean of Graduate Studies, and the 2004 recipients of the VC's Excellence in
Research Supervision Awards, Professors Christodoulou and Kuchel.
(6)
Presentation at the Techniques Seminar Series and Discussion Papers for Honours Students
(2005, 2006, 2007) Department of Pathology, School of Medical Sciences, University of Sydney.
(7)
Postgraduate Supervisor Registration: Completion of the University of Sydney postgraduate
Institute for Teaching and Learning (on-line) Course, (December 2005, certificate awarded
February 2006).
(8)
Special (two-day) lecture series to undergraduate medical sciences students (3rd year) as part of
the Molecular Medicine Syllabus, Griffith University (October, 2005 and November, 2006).
(9)
Redesigning and up-dating the ANZAC Research Institute website.
(10) Attendance at the ChemAlert Departmental Training Lectures (June 2007; Vivienne Bush –
Concord Hospital ChemAlert II site administrator).
______________________________________________________
x
______________________________________________________
List of Peer-reviewed Publications:
(W1)
Harsanyi M.C., Lay P.A., Norris R.K., and Witting P.K. The Reduction of Bridgehead Halogens
by an Intramolecular Electron Transfer Mechanism. J. Org. Chem., 1995, 60, 5487-5493. (IF –
3.8)
(W2)
Harsanyi M.C., Norris R.K., Sze G., and Witting P.K., Substituent Dependent Nitration of 9Substituted 9,10-dihydro-9,10-ethanoanthracenes. Aust. J. Chem., 1995, 48, 1949-1967. (IF –
1.9)
(W3)
Witting P.K., Bowry V.B., and Stocker R. A Deuterium Kinetic Isotope Effect for Lipid
Peroxidation in Human Low Density Lipoprotein (LDL): A Simple test for peroxyl vs antioxidant
radical mediated peroxidation of lipid dispersions. FEBS Lett., 1995, 375, 45-49. (IF – 3.4)
(W4)
Witting P.K., Westerlund C., and Stocker R. A Rapid and Convenient Screening Test for
Inhibitors of Tocopherol-mediated Peroxidation of LDL Lipids. J. Lipid Res., 1996, 37, 853-867.
(IF – 4.4)
(W5)
Harsanyi M.C., Lay P.A., Norris R.K., and Witting P.K. Substitution of Bridgehead Halogens by
an Intramolecular Free Radical Electron Transfer Mechanism. Aust. J. Chem., 1996, 49, 581598. (IF – 1.9)
(W6)
Manny A.J., Norris R.K., and Witting P.K. Substituent Dependent Electron Transfer in Radical
Anions
of
9-Substituted
and
9,10-Disubstituted
2,7-Dinitro-9,10-dihydro-9,10ethanoanthracenes. Mag. Res. Chem., 1996, 34, 761-767. (IF – 1.6)
(W7)
Lass A., Witting P.K., Stocker R., and Esterbauer H. Inhibition of Copper(II)- and Peroxyl
Radical-induced LDL Lipid Oxidation by Ebselen: Antioxidant activity in addition to
hydroperoxide reducing activity. Biochim. Biophys. Acta, 1996, 1303 (2), 111-118. (IF – 5.8)
(W8)
Lay P.A., Norris R.K., and Witting P.K. Cyclic Voltammetric and Electron Paramagnetic Studies
of 9-Substituted and 9,10-Disubstituted ethanoanthracenes. Aust. J. Chem., 1996, 49, 12791286. (IF – 1.9)
(W9)
Thomas S.T., Witting P.K., and Stocker R. 3-Hydroxyanthranilic Acid is an Efficient
Physiological Co-antioxidant for
-Tocopherol: Inhibition of human low-density lipoprotein and
plasma lipid peroxidation by a macrophage-derived antioxidant. J. Biol. Chem., 1996, 271 (51),
32714-32721. (IF – 5.8)
(W10) Witting P.K., and Stocker R. Reduction of a Water-soluble Nitroxide by Human Low Density
Lipoprotein. Mag. Res. Chem., 1997, 35, 100-106. (IF – 1.6)
(W11) Witting P.K., Upston J.M., and Stocker R. Formation of
-Tocopheroxyl Radical Initiates Lipid
Peroxidation in LDL Exposed to Horse Radish Peroxidase. Biochemistry 1997, 36, 1251-1258.
(IF – 3.6)
______________________________________________________
xi
______________________________________________________
(W12) Neuzil J., Witting P.K., and Stocker R.
-Tocopheryl Hydroquinone a Potent and Multifunctional
Inhibitor of Human Low Density Lipoprotein Lipid Peroxidation. Proc. Natl. Acad. Sci. USA,
1997, 94, 7885-7890. (IF – 10.5)
(W13) Lay P.A., Norris R.K., and Witting P.K. Electrochemical Studies on the Competition Between
Intramolecular Protonation of Nitroaryl Radical Anions in the Reduction of Apical Carboxylic
Acid Substituents of 2- and 3-Nitro-9,10-dihydro-9,10-ethanoanthracene-9-carboxylic acid.
Aust. J. Chem., 1997, 50, 999-1007. (IF – 1.9)
(W14) Upston J.M., Neuzil J., Witting P.K., and Stocker R. Oxidation of Free Fatty Acids in Human
Low Density Lipoprotein by 15-Lipoxygenase Stimulates Non-enzymic
-Tocopherol-mediated
Peroxidation of Cholesteryl Esters. J. Biol. Chem., 1997, 272, 30067-30074. (IF – 5.8)
(W15) Garner B., Witting P.K., Waldeck A.R., Christison J.K., Raftery M., and Stocker R. Oxidation of
High Density Lipoproteins. I. Methionine sulfoxide formation in apolipoprotein AI/AII is an early
event accompanying lipid peroxidation and can be enhanced by -tocopherol. J. Biol. Chem.,
1998, 273, 6080-6087. (IF – 5.8)
(W16) Garner B.,Waldeck A.R., Witting P.K., Rye K.A., and Stocker R. Oxidation of High Density
Lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of
apolipoprotein AI and AII. J. Biol. Chem., 1998, 273, 6088-6094. (IF – 5.8)
(W17) Neuzil J., Upston J.M., Witting P.K., Scott K.F., and Stocker R. Secretary Phospholipase A2
and Lipoprotein Lipase Enhance 15-Lipoxygenase-induced Enzymic and Nonenzymic Lipid
Peroxidation in Low Density Lipoprotein. Biochemistry 1998, 37, 9203-9210. (IF – 3.6)
(W18) Witting P.K., Mohr D., and Stocker R. Assessment of the Pro- and Antioxidant Activity of
Vitamin E in Human Low Density Lipoprotein and Plasma. Methods Enzymol., 1998, 299, 362375. (IF – 1.6)
(W19) Witting P.K., Pettersson K., Östland-Lindquist A-M., Westerlund C., Westin-Ericsson A., and
Stocker R. Inhibition of Intimal Lipid Peroxidation and Atherosclerosis in Apolipoprotein E and
LDL receptor deficient mice fed the Probucol metabolite H212/43. FASEB J., 1999, 13, 667675. (IF – 6.7)
(W20) Letters J.M., Witting P.K., Christison J.M., and Stocker R. Changes to Lipids and Antioxidants
in Plasma and Aortae of Apolipoprotein E Deficient Mice Receiving the Western Diet. J. Lipid
Res., 1999, 40, 1104-1112. (IF – 4.4)
(W21) Witting P.K., Pettersson K., Östland-Lindquist A-M., Westerlund C., Wåberg M., and Stocker R.
Dissociation between the Inhibition of Intimal Lipid peroxidation and Atherosclerosis in
Watanabe Heritable Hyperlipidemic Rabbits. J. Clin. Invest., 1999, 104, 213-220. (IF – 15.8)
______________________________________________________
xii
______________________________________________________
(W22) Witting P.K., Willhite C.A., Davies M.J., and Stocker R. Oxidation of Low Density Lipoprotein by
Metmyoglobin/H2O2: Involvement of
-tocopheroxyl radical then alkoxyl radicals derived from
phosphatidycholine hydroperoxides upon depletion of vitamin E. Chem. Res. Toxicol., 1999,
12, 1173-1181. (IF – 3.2)
(W23) Raitakari O.T., McCredie R.J., Letters J.L., Witting P.K., Griffiths K.A., Sullivan D., Stocker R.,
and Celermajer D.S. Coenzyme Q Supplementation Improves LDL Resistance to Oxidation but
does not Enhance Endothelial Function in Young Adults with Moderate Hypercholesterolemia.
Free Radic. Biol. Med., 2000, 28, 1100-1105. (IF – 5.4)
(W24) Witting P.K., Letters J.L., Pettersson K., and Stocker R. Site specific Pro- and Antiatherogenic
Effects of Probucol in Apo E-deficient Mice. Arterioscl. Thromb. Vasc. Biol., 2000, 20, 26e-33e.
(IF – 7.4)
(W25) Witting P.K., Douglas D.J., and Mauk A.G. Reaction of Recombinant Human Myoglobin and
H2O2: A role for the thiyl radical produced at cysteine 110? J. Biol. Chem., 2000, 275, 2039120398. (IF – 5.8)
(W26) Lau A.K., Witting P.K., Chaufour X., Celermajer D.S., and Stocker R. Protective Effects of
Probucol in two Animal Models of Atherosclerosis. Redox Report 2000, 5, 116-118. (IF – 1.6)
(W27) Witting P.K., Pettersson K., Letters J.L., and Stocker R. Antiatherogenic Effect of Coenzyme
Q-10 in Apolipoprotein E-deficient Mice. Free Radic. Biol. Med., 2000, 29, 295-305. (IF – 5.4)
(W28) Witting P.K., Douglas D.J., and Mauk A. G. Reaction of Human Myoglobin and Nitric oxide:
Formation of heme iron- or sulfhydryl (S)-nitrosated protein dependence on the absence or
presence of oxygen. J. Biol. Chem., 2001, 276, 3991-3998. (IF – 5.8)
(W29) Travascio P., Witting P.K., Mauk A.G., and Sen D. The Peroxidase Activity of a Hemin-DNA
Oligonucleotide Complex: Free radical damage to specific guanine bases of DNA. J. Am.
Chem. Soc., 2001, 123, 1337-1348. (IF – 7.7)
(W30) Witting P.K., and Mauk A.G. Reaction of Human Myoglobin and H2O2: Electron transfer
between tyrosine phenoxyl radical and cysteine in human myoglobin yields a protein-thiyl
radical. J. Biol. Chem., 2001, 276, 16540-16547. (IF – 5.8)
(W31) Witting P.K., Mauk A.G., Douglas D.J., and Stocker R. Reaction of Human Myoglobin and
Peroxynitrite: Characterising biomarkers for myoglobin-derived oxidative stress.
Biochem.
Biophys. Res. Commun., 2001, 286, 352-356. (IF – 2.9)
(W32) Witting P.K., Travascio P., Sen D., and Mauk A.G. A DNA-oligonucleotide Hemin Complex
Decomposes t-Butyl Hydroperoxide through a Homolytic Mechanism. Inorg. Chem., 2001, 40,
5017-5023. (IF – 3.5)
______________________________________________________
xiii
______________________________________________________
(W33) Upston J.M., Witting P.K., Brown A.J., Stocker R., and Keaney J.F. Jr.
Effect of Dietary
Vitamin E on Aortic Lipid Oxidation and Intimal Proliferation after Balloon Injury in Cholesterolfed Rabbits. Free Radic. Biol. Med., 2001, 31, 1245-1253. (IF – 5.4)
(W34) Brasen J.H., Koenig K., Bach H., Heinle H., Kontush A., Heinle H., Witting P.K., Yla-Herttuala
S., Stocker R., and Beisegel U. Comparison of the Effects of -Tocopherol, Ubiquinone-10 and
Probucol at Therapeutic doses on Atherosclerosis in WHHL Rabbits. Atherosclerosis 2002,
163, 249-259. (IF – 3.6)
(W35) Witting P.K., Mauk A.G., and Lay P.A.
Effect of the Tyr103Phe Point Mutation in Human
Myoglobin on Reaction with H2O2: A Kinetic and steady-state analyses. Biochemistry 2002,
41, 11495-11503. (IF – 3.6)
(W36) Weber T., Dalen H., Andera L., Nègre-Salvayre A., Sticha M., Pallardo F.V., Terman A., Witting
P.K., Higuchi M., Plasilova M., Zivny J., Gellert N., Weber C., and Neuzil J. Mitochondria Play a
Central Role in Apoptosis Induced by -Tocopheryl Succinate, an Agent with Antineoplastic
Activity: Comparison with Receptor-Mediated Pro-Apoptotic Signaling. Biochemistry 2003, 42,
4277-4291. (IF – 3.6)
(W37) Choy K.J., Deng Y-M., Hou H., Wu B., Lau A., Witting P.K., and Stocker R. Coenzyme Q10
supplementation inhibits aortic lipid oxidation but fails to attenuate intimal thickening in ballooninjured New Zealand White rabbits. Free Radic. Biol. Med., 2003, 35, 300-309. (IF – 5.4)
(W38) Rayner B.S., Stocker R., Lay P.A., and Witting P.K. Regio- and stereo-chemical oxidation of
linoleic acid by human myoglobin and hydrogen peroxide: Tyrosine residue 103 affects rate
and product distribution. Biochem. J., 2004, 381. 365-372. (IF – 4.1)
(W39) Deng Y-M., Wu B-J., Witting P.K., and Stocker R. Probucol protects against intimal thickening
by up-regulating vessel content of heme oxygenase-1. Circulation, 2004, 110, 1855-1860. (IF –
12.8)
(W40) Rayner B.S., Wu B-J., Stocker R., and Witting P.K.
Regulation of vascular tone by S-
nitrosomyoglobin. Redox Report, 2004, 9, 382-386. (IF – 1.6)
(W41) Wang X.F., Witting P.K., Salvatore B.A., and Neuzil J. Vitamin E analogues trigger apoptosis in
erbB2-overexpressing cancer cells by signalling via the mitochondrial pathway.
Biochem.
Biophys. Res. Commun., 2005, 326, 282-289. (IF – 3.0)
(W42) Rayner B.S., Wu B-J., Raftery M., Stocker R., and Witting P.K. Human S-nitroso-oxymyoglobin
is a store of vasoactive nitric oxide. J. Biol. Chem., 2005, 280, 9985-9993. (IF – 5.8)
______________________________________________________
xiv
______________________________________________________
(W43) Witting P.K.,* Wu B-J.,* Raftery M., Southwell-Keely P., and Stocker R. Probucol protects
against HOCl-induced endothelial dysfunction.
Identificaton of novel pathway of probucol
oxidation to a biologically active intermediate. J. Biol. Chem., 2005, 280, 15612-15618 (*
contributed equally to the manuscript). (IF – 5.8)
(W44) Stapelberg M., Gellert N., Swettenham E., Tomasetti M., Witting P.K., Smith R.A.J., Murphy
M.P., and Neuzil J. -Tocopheryl succinate inhibits malignant mesothelioma by disrupting the
FGF autocrine loop: Mechanism and the role of oxidative stress. J. Biol. Chem., 2005, 280,
25369-25376. (IF – 5.8)
(W45) Swettenham E., Witting P.K., Salvatore B.A., and Neuzil J.
-Tocopherylsuccinate
induces
apoptosis in neuroblastoma cells: Novel therapy against brain tumours? J. Neurochemistry,
2005, 94, 1448-1456. (IF – 4.3)
(W46) Rayner B.S., Duong T.T.H., Myers S.J., Witting P.K. Protective effect of a synthetic antioxidant
on neuronal cell apoptosis resulting from experimental hypoxia re-oxygenation injury. J.
Neurochem. 2006, 97, 211-21. (IF – 4.3)
(W47) Wu B-J., Kathir K., Witting P.K., Beck K., Choy K., Li C., Croft K.D., Mori T.P.K., Tanous D.,
Adams M.R., Lau A.K., and Stocker R. Antioxidants protect from atherosclerosis by a heme
oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med. 2006, 203,
1117-11727. (IF – 14.5)
(W48) Hack B.,* Witting P.K.,* Rayner B.S., Stocker R., and Headrick J.P. The relation between
oxidant stress and damage and myocardial injury in post-ischemic mouse hearts: Effects of
adenosine and pyruvate. Mol. Cell. Biochem., 2006, 287, 165-175. (*contributed equally to the
manuscript). (IF – 1.9)
(W49) de Haan J.B., Witting P.K., Stefanovic N., Pete J., Daskalakis M., Kola I., Stocker R., and
Smolich J.J. Eliminating glutathione peroxidase-1 (Gpx1) does not lead to increased
atherosclerosis in mice fed a high fat diet. J. Lipid Res. 2006, 47, 1157-1167. (IF – 4.4)
(W50) Witting P.K., Liao W-Q., Harris M.J., and Neuzil J. Expression of wild-type and the Y103F
variant of human myoglobin in H9c2 myocyte-like cells enhances toxicity toward added
hydrogen peroxide. Biochem. Biophys. Res. Commun., 2006, 348, 485-93. (IF – 2.9)
(W51) Witting P.K., Harris H.H., Rayner B.S., Aitken J.B., Dillon C.T., Stocker R., Lai B., Cai Z., and
Lay P.A. The Endothelium-derived Hyperpolarizing Factor, H2O2, Promotes Metal-ion Efflux in
Aortic Endothelial Cells: Elemental Mapping by a Hard X-ray Microprobe. Biochemistry, 2006,
45, 12500-12509 (IF – 3.6)
______________________________________________________
xv
______________________________________________________
(W52) Neuzil J., Widén C., Gellert N., Swettenham E., Dong L-F., Wang X-F., Neuzilova R., Liao W-
Q., Lidebjer C., Dalen H., Headrick J.P., and Witting P.K. Mitochondria-derived superoxide
induces apoptosis in cardiac myocytes exposed to experimental ischemia-reperfusion injury.
Redox Report. 2007, 12, 148-162 (IF – 1.6)
(W53) Witting P.K., Rayner B.S., Wu B-J., Ellis N.A., and Stocker R. Hydrogen peroxide promotes
vascular dysfunction through decreasing nitric oxide bioavailability. Cell Physiol. Biochem,
2007, 20, 255-268 (IF – 3.6)
(W54) Dong L-F., Swettenham E., Eliasson J., Wang X-F., Gold M., Medunic Y., Stantic M., Low P.,
Prochazka L., Witting P.K., Turanek J., Akporiaye E.T., Ralph S.J., Neuzil J. Vitamin E analogs
inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: The
role of oxidative stress. Cancer Res. 2007, 67, 11906-11913 (IF – 7.8)
(W55) Parry S.N., Ellis NA, Li Z., Maitz P., Witting P.K. Myoglobin induces oxidative stress and
decreases endocytosis and monolayer permissiveness in cultured kidney epithelial cells without
affecting viability. Kidney and Blood Press. Res. 2008, 31, 16-28 (IF – 1.9)
(W56) Dong L-F., Low P., Dyason J.C., Wang X-F., Prochazka L., Witting P.K., Swettenham E.,
Turanek J., Spitz D.R., Domann F.E., Scheffler I.E., Ralph S.J., and Neuzil J. Ubiquinonebinding sites in the mitochondrial respiratory complex II as a new anti-cancer target.
Oncogene. 2008, in press. (IF – 6.3)
(W57) Witting P.K., Zeng B., Wong M., McMahon A.C., Rayner B.S., Sapir A.J., Lowe H.C.,
Freedman S.B., and Brieger D. Polymorphonuclear Leucocyte Phagocytic Function is
Enhanced in Plasminogen Knockout Mice. Thromb. Research. 2008, in press. (IF – 2.1)
(W58) Song C., Shen Y., Yamen E., Hsu K., Yan W., Witting P.K., Geczy C.L., and Freedman S.B.
Serum amyloid A may potentiate prothrombotic and pro-inflammatory events in acute coronary
syndromes. Atherosclerosis 2008, in press. (IF – 3.6)
(W59) Duong T.T.H., Antao S.A., Parry S.N. Ellis N.A., Myers S.J., Witting P.K. Gene regulation and
apoptosis in cultured human neuronal cells exposed to hypoxia re-oxygenation injury as a
model for stroke. Brain Res. 2008, in press. (IF – 2.4)
(W60) Niknami M., Dong Q., Witting P.K. Pitfalls in the assessment of lipoxygenase activity in cancer
cells. Brit. J. Cancer. 2008, in press (IF 4.5)
(W60)
Szuchman-Sapir A., Pattison D.I., Ellis N.A., Hawkins C.L., Davies M.J., Witting P.K. Reagent
or neutrophil-derived hypochlorous acid oxidizes methionine and tryptophan residues in horse
heart myoglobin. 2008, Free Radic. Biol. Med. submitted. (IF – 5.4)
______________________________________________________
xvi
______________________________________________________
(W61)
Reichelt M.E., Willems L., Witting P.K., Ellis N.A., Blackburn M., and Headrick J.P. A1
adenosine receptor deletion selectively augments oxidant stress in ischemic mouse heart. J.
Mol. Cell Cardiol. 2008, submitted. (IF – 4.5)
(W62)
Liu H., Keaney J.F. Jr, Wu B-J., Witting P.K., Thomas S.R., Hunt N.H. and Stocker R.
Kynurenine is a novel endothelium-derived relaxing factor. Nature Med. 2008, resubmitted. (IF
– 32)
(W63)
Sabaretnam T., Harris M.J., Kockx M., Witting P.K., Le Couteur D.G., Kritharides L. The
effects of oxidative stress, aging and apoE isoforms on hepatocellular apoE trafficking. J
Hepatol 2008 submitted (IF – 4.8)
(W64)
Tiong A.Y., Song C-J., Witting P.K., Myers S.J., Jimenez M., DeWinter J., Freedman B.S.,
and Brieger D. Plasma MMP-9 nd TIMP-1 in Patients with Symptomatic Coronary Artery
Disease. Thromb. Haemo. 2008, submitted. (IF – 3.1)
(W65)
Duong T.T.H..* Witting P.K.,* Lai B., Vogt S., Lay P.A., Harris H.H. Neuroglobin overexpression protects cultured neuronal cells by decreasing oxidative stress and preserving
total cellular ion density and mitochondrial function. Manuscript in preparation. (*contributed
equally to the manuscript)
(W66)
Lay P.A., Levina A., Ellis N.A., and Witting P.K. Electron transfer kinetics in a Y103F variant
of human myoglobin. J. Biol. Chem. 2007, manuscript in preparation.
(W67)
Carter E.A., Rayner B.S., Harris H.H., Wu L.E., Marshall C.P., Levina A., Witting P.K., Lai B.,
Cai Z., Vogt S., Lee Y-C., Chen C-I., Lay P.A. Silicon Nitride as a Universal Substrate for
Synchrotron Microspectroscopy of Whole Cells. Nature Methods, manuscript in preparation.
xvii
______________________________________________________
xviii
______________________________________________________
Book Chapters and Review Articles:
(W67) Witting P.K., Upston J., and Stocker R. The Molecular Action of -Tocopherol in Lipid
Oxidation: Pro- and antioxidant activity of vitamin E in complex lipid emulsions. In Subcellular
Biochemistry: Fat-soluble vitamins. 1998, Ed.s Kagan V., and Quinn P.J., Plenum Press,
London, p345-390.
(W68) Thomas S.R., Witting P.K., and Stocker R. A Role for Coenzyme Q10 in Atherosclerosis?
Biofactors, 1999, 9, 207-224.
(W69) Pettersson K.S., Witting P.K., and Stocker R. Antioxidant Intervention Studies in Animals. In
Atherosclerosis: Gene Expression, Cell Interactions and Oxidation, 2000, Eds Dean R.T., and
Kelly D.T., Oxford University Press, 2001: New York, p46-67.
(W70) Mashima R., Witting P.K., and Stocker R. Oxidants and Antioxidants. Curr. Opin. Lipidol.,
2001, 12, 411-418.
(W71) Andriambeloson E., and Witting P.K. Chemical regulation of Nitric Oxide:
A role for
intracellular myoglobin? Redox Report 2002, 7, 131-136.
(W72) Witting P.K., and Stocker R. Ascorbic acid as an antioxidant in atherosclerosis. In Vitamin C: it
functions and biochemistry in animals and plants. Eds May J.M., Hasard A., and Smirnoff N.
Bios Scientific Publishers, 2004: Oxford (UK) p261-290.
(W73) Neuzil J., Rayner B.S., Lowe H.C., and Witting P.K. Oxidative stress in myocardial ischemia
reperfusion injury: a renewed focus on a long-standing area of heart research. Redox Report,
2005, 10, 187-197.
(W74) Neuzil J., Witting P.K., Kontush A., and Headrick J.P. Role of vitamins E and C in nuclear
factor-kB and nitric oxide signaling. In Encyclopedia of Vitamin E; Section 12 Cancer. Preedy
V, Watson R, Eds, CABI Publishing 2006: London (UK).
(W75) Bhindi R., Witting P.K., McMahon A.C., Kachigian L., and Lowe H.C. Rat models of myocardial
infarction. Pathogenetic insights and clinical relevance. Thromb. Haemost. 2006, 96, 602-610.
(W76) McMahon A.C., Duong T.T.H., Brieger D., and Witting P.K. Scope for antioxidants to enhance
thrombolytic therapies in stroke patients. Future Cardiology. 2006, 2, 659-665.
(W77) Nikinami M., Patel M., Witting P.K., and Dong Q. Aberrant activation of arachidonic acid and
eicosanoid pathways-targets for treating prostate cancer. Recent Patents on Endocrine,
Metabolic & Immune Drug Discovery Bentham Science Publishers Ltd, Volume 2, Issue 1, p915, January 2008.
(W78) Thomas S.R., Drummond G., and Witting P.K. Redox Signaling in Endothelial Function and
Dysfunction: Molecular Mechanisms and Therapeutic Options. Antiox. Redox Signaling. 2008,
in press.
______________________________________________________
xix
______________________________________________________
Published Conference abstracts or Proceedings:
(W79) Stocker R., Upston J.M., Neuzil J., and Witting P.K. Mechanism of 15-Lipoxygenase-induced
LDL Lipid Peroxidation. J. Mol. Cell Cardiol., 1997, 29, A268.
(W80) Thomas S.R., Witting P.K., and Stocker R. Macrophage-derived 3-hydroxyanthranilate
synergies with vitamin E in inhibiting LDL lipid peroxidation. Atherosclerosis 1997, 134, S236.
(W81) Witting P.K., Douglas D.J., and Mauk A.G. Reaction of Human Myoglobin and NO: Heme iron-
or protein sulfhydryl (S)-nitrosation. Free Radic. Biol. Med., 2000, 29, S77.
(W82) Witting P.K., Douglas D.J., Mauk A.G. Reaction of human myoglobin and hydrogen peroxide:
Involvement of a thiyl radical produced at C110. American Chemical Society, 2000, 220, S249.
(W83) Stocker R., Witting P.K., Upston J.M., Thomas S.R., Terentis A.C., Lau A.L., Leichtweis S.,
Chafour C., Burr J.A., Liebler D.C., and Pettersson K. Evidence for the Dissociation of
Lipoprotein Lipid Peroxidation and Atherosclerosis in Different Animals. Atherosclerosis 2000,
151, S234.
(W84) Lau A., Leichtweis S., Chaufour X., Witting P.K., Celermajer D.S., and Stocker R. Probucol
promotes re-endothelialization after balloon injury, AHA, 73rd Scientific Session. Circulation
2000, 102, SII-317.
(W85) Mauk A.G., Hunter C.L., Witting P.K., Maurus R., and Brayer G.D. New Ligand Binding Options
for Human and Engineered Horse Myoglobins. J. Inorg. Biochem., 2001, 86, S72.
(W86) Aitken J.B., Thomas S.E., Armstrong R.S., Lay P.A., Stocker R., Witting P.K., Dillon C.T., and
Lai B. Investigation of indoleamine 2,3-dioxygenase using synchrotron radiation techniques. J.
Inorg. Biochem., 2003, 96: S87.
(W87) Wu B., Hou J.Y., Choy K., Lau A., Witting P.K., and Stocker R. Inhibition of intimal thickening
after balloon injury by sulfur-containing phenolic antioxidants. Clin. Exp. Pharmacol. Physiol.
2003, 30, A15.
(W88) De Haan J.B., Stefanovic N., Stocker R., Witting P.K., Kola I., Herztog P., and Smolich J. A
reduction in antioxidant glutathione peroxidase 1 enzyme contributes to vascular oxidative
stress in an animal model of atherosclerosis. Heart Lung and Circulation, 2003, 12, A76.
(W89) Aitken J., Dillon C.T., Lay P.A., Stocker R., Witting P.K., Cai Z., Lai B. Report to the Advanced
Photon Source, USA. Induction of Indoleamine-2,3-dioxygenase (IDO) in Porcine Aortic
Endothelial Cells 2004. This research was supported by the Australian Synchrotron Research
Program, which is funded by the Commonwealth of Australia under the Major National
Research Facilities program. The Advanced Photon Source is supported by the U.S.
Department of Energy, Office of Science
______________________________________________________
xx
______________________________________________________
(W90)
Lay P.A., Dillon C.T., Harris H.H., Aitken J., Levina A., Mulyani I., Lai B., Cai Z., Vogt S.,
Witting P.K., Thomas SR, Stocker R, Eastgate H. Probing Metal Ions in Biology with X-ray
Absorption Spectroscopy, Frontiers in Bio-Metals, University of Saskatchewan, Canada 2005.
(W91)
Carter E.A., Marshall C.P., Rayner B.S., Lee Y-C., Chen C-I., Witting P.K., Lay P.A. Activity
Report to the National Synchrotron Radiation Research Center, Hsinchu, Taiwan, 2005.
Infrared Spectroscopy of Biological Samples: Cells and Microbial Fossils. This research was
supported by the Australian Synchrotron Research Program, which is funded by the
Commonwealth of Australia under the Major National Research Facilities Program, a National
Heart Foundation PhD scholarship to BSR and an ARC Fellowship to PKW.
(W92)
Tiong A., Song C.J., Witting P.K., Freedman B., Brieger D. Acute activation of systemic T cells
during plaque instability is associated with increased net plasma MMP-9 activity. Eur. Heart J.
2006, 27 (Suppl. 1), 447-447.
(W93)
Rayner B.S., Harris H.H., Carter E., Vogt S., Cai Z., Lai B., Chin C., Lee Y., Lay P.A., Witting
P.K. Use of synchrotron radiation to measure ion flux and cellular protein and lipid changes
within cardiac ischemia reperfusion injury. Atherosclerosis Supplements, 2006, 7, 587-587.
(W94)
Rayner B.S., Carter E.A., Lee Y-C., Chen C-I., Witting P.K., Lay P.A. Activity Report to the
National Synchrotron Radiation Research Center, Hsinchu, Taiwan. IR Spectroscopy of
Biological Samples: Ischemic injury to cardiac tissue and the effect of pre-treatment with
antioxidants. The research was supported by the Australian Synchrotron Research Program,
which is funded by the Commonwealth of Australia under the Major National Research
Facilities Program, a National Heart Foundation PhD scholarship to BSR and an ARC
Fellowship to PKW.
(W95)
Rayner B.S., and Witting P.K. A synthetic polyphenol limits hydrogen peroxide-induced cell
death in H9c2 myocyte-like cells. Journal of Heart Disease. 2007, A335, 84.
(W96)
Rayner B.S., and Witting P.K. A synthetic polyphenol limits hydrogen peroxide-induced cell
death in H9c2 myocyte-like cells. Proceedings of the World Congress on Heart Disease,
(Vancouver). 2008 In press.
Patents Held:
(W97) Östland-Lindqvist A-M., Pettersson K., Stocker R., Westerlund C., and Witting P.K. (February
29, 2000). United States Patent 6,031,008; Australian Letters Patent 711275; New Zealand
Letters Patent 332196; Singapore Patent P-57011; Canada Patent 2251269; Europe Patent
(Austria, Belgium, Denmark, Finland, Germany, Greece, Ireland, Luxemburg, Monaco,
Netherlands,
Portugal,
Spain,
Sweden,
Switzerland/Leichtenstein,
United
Kingdom)
97919834.8; Hong Kong and Japan.
______________________________________________________
xxi
______________________________________________________
Abstracts/invited presentations: (Presenting author, * indicates oral presentation by PKW):
(1)
Royal Australian Chemical Institute (R.A.C.I.) Conference, Brisbane, 1991: Intramolecular
Electron Transfer in Nitroethanoanthracenes; an electrochemical and EPR spectroscopic
study, P.K. Witting, and P.A. Lay, and R.K. Norris.
(2)
The 9th National R.A.C.I. Meeting, Melbourne, 1992: Substitution of 2- and 3-Nitro-9-iodo-9,10ethanoanthracenes and Estimates of Rate Constants for Intramolecular Electron Transfer
Processes by using Cyclic Voltammetry, P.K. Witting, P.A. Lay, and R.K. Norris.
(3)
*
The Joint Electrochemistry Research Colloquium, Sydney, 1992: Estimates of Rate
Constants for Intramolecular Electron Transfer in the One-electron Reduction of 2- and 3-Nitro9-iodo-9,10-ethanoanthracenes using Cyclic Voltammetry, P.K. Witting, P.A. Lay, and R.K.
Norris.
(4)
* 7th Biennial ISFRR meeting: Sydney, 1994: The Interaction of Nitroxide Spin labels and Nitric
Oxide with Human Low Density Lipoprotein, P.K. Witting, and R. Stocker.
(5)
*
The SFRR(A), Wollongong, 1995: A Rapid and Convenient Screen-test for Potential
Inhibitors of Tocopherol Mediated-Peroxidation of Human LDL, and The Inverse Deuterium
Kinetic Isotope Effect for Peroxidation of Human Low-density Lipoprotein [LDL]:
Further
evidence supporting tocopherol mediated-peroxidation of LDL lipids, P.K. Witting, V.W. Bowry,
C. Westerlund, and R. Stocker.
(6)
* (invited oral presentation) 8th Biennial ISFRR meeting, Barcelona Spain, 1996: Oxidation
of
-Tocopherol by Horse Radish Peroxidase Initiates Lipid Oxidation in Human LDL, P.K.
Witting, J.M. Upston, and R. Stocker., and A Rapid and Convenient Screen-test for Potential
Inhibitors of Tocopherol Mediated-Peroxidation of Human LDL, P.K. Witting, J.M. Upston, C.
Westerlund, and R. Stocker.
(7)
International Society of Heart Research, Vancouver, 1997: Mechanism of Human Recombinant
15-Lipoxygenase induced LDL Lipid Peroxidation, R. Stocker, J. Neuzil, J.M. Upston, and P.K.
Witting.
(8)
11th International Symposium on Atherosclerosis, Paris, 1997: Macrophage-Derived 3Hydroxyanthranilic Acid Synergises with Vitamin E and Prevents Human Plasma and LDL Lipid
Peroxidation, S.R. Thomas, P.K. Witting, and R. Stocker.
(9)
Satellite Symposia for the 11th International Atherosclerosis Symposium, Royamount France,
1997: Mechanism of human LDL Lipid Peroxidation, R. Stocker, L. Hazell, J. Neuzil, S.R.
Thomas, J.M. Upston, and P.K. Witting.
______________________________________________________
xxii
______________________________________________________
(10)
* (invited oral presentation) Australian Atherosclerosis Society, Leura, 1997: Determination
of Lipoprotein Profile, Lipid Oxidisability, Concentration of Lipids and Antioxidants for both
Plasma and Aortae of Apolipoprotein E-deficient Mice fed a High-fat Western Diet, P.K.
Witting, J.M. Letters, J.L. Christison, and R. Stocker.
(11)
Oxygen Society Meeting, Los Angeles, 1997: -Tocopheryl Hydroquinone is a Potent and
Multifunctional Inhibitor of Human Low Density Lipoprotein Lipid Peroxidation, J. Neuzil, P.K.
Witting, and R. Stocker, and Lipases Enhance Tocopherol-mediated Peroxidation of Human
LDL lipids Induced by 15-Lipoxygenases, J. Neuzil, J.M. Upston, P.K. Witting, K. Scott, and R.
Stocker.
(12)
* (invited oral presentation) Meeting of the Australian Society for Clinical Biochemists,
Brisbane, 1998: Antioxidants, what are they? P.K. Witting.
(13)
* (invited oral presentation)
9th Biennial ISFRR meeting, São Paulo, Brazil 1998:
Dissociation between the Inhibition of Intimal Lipid peroxidation and Atherosclerosis in
Watanabe Heritable Hyperlipidemic Rabbits, P.K.Witting, K. Pettersson, A-M. ÖstlandLindquist, C. Westerlund, M. Wåberg, and R. Stocker.
(14)
* SFRR (Australasia) Annual meeting, Melbourne 1998, Oxidation of Low Density Lipoprotein
by Metmyoglobin/H2O2: Involvement of -tocopheroxyl and alkoxyl radicals derived from
phosphatidycholine hydroperoxides. P.K. Witting, C.A. Willhite, M.J. Davies, and R. Stocker.
(15)
American
Heart
Association
meeting,
Boston,
June
2000:
Probucol
promotes
re-
endothelialization after balloon injury, A. Lau, S. Leichtweis, X. Chaufour, P.K. Witting, D.S.
Celermajer, and R. Stocker.
(16)
7th Annual Oxygen Society meeting, San Diego, November 2000: Reaction of Human
Myoglobin and Nitric Oxide: Heme iron- or protein sulfhydryl (S)-nitrosation dependence on the
absence or presence of oxygen, P.K. Witting, D. J. Douglas and A. Grant Mauk.
(17)
* (invited oral presentation) Chemistry Department, Macquarie University – Departmental
Seminar August 2001: Chemical and molecular aspects of engineered myoglobin. P.K. Witting.
(18)
* (invited oral presentation) 10th Joint Meeting of the Societies for Free Radical Research
(Australasia and Japan), Sydney, December 2001: Role for myoglobin in the regulation of
endothelial-derived relaxant factor? P.K. Witting.
(19)
Australian Vascular Biology Meeting, Hunter Valley NSW, Aug 2002: Probucol enhances heme
oxygenase-1 gene expression in rabbit aorta after balloon injury. Y-M Deng, P.K. Witting, B-J
Wu, and R. Stocker.
(20)
* Australian Atherosclerosis Society Meeting, Sydney Oct 2002: Inhibition of intimal thickening
after balloon injury by sulfur-containing phenolic antioxidants. P.K. Witting, B-J. Wu, J-Y. Hou,
K. Choy, A. Lau, and R. Stocker.
______________________________________________________
xxiii
______________________________________________________
(21)
* (invited oral presentation) 11th Meeting of the Society for Free Radical Research
(Australasia), Wollongong, December 2002: Role for myoglobin in myocardial reperfusion
damage? P.K. Witting.
(22)
* (invited oral presentation) School of Chemistry, University of Sydney – School Seminar
August 2003: Peroxidase chemistry of myoglobin. P.K. Witting.
(23)
Annual Meeting of the Cardiac Societies of Australia and New Zealand, Adelaide 2003: An
animal model of type-2 diabetes. K. Kathir, B-J Wu, P.K. Witting, M.R. Adams, and R. Stocker.
(24)
* (invited oral presentation) Heart Foundation Institute (Griffith University, Gold Coast)
October 2003: Pathological role for myoglobin in the promotion of myocardial reperfusion
damage. P.K. Witting.
(25)
11th Meeting of the International Society for Bio-inorganic Chemistry (ICBIC 11), Cairns 2003.
Investigation of Indoleamine 2,3-dioxygenase with Synchrotron Radiation techniques. J.B.
Aitken, S.E. Thomas, R. Stocker, S.R. Thomas, P.K. Witting, C.T. Dillon, R.S. Armstrong, P.A.
Lay, B. Lai.
(26)
* (invited oral presentation) Food Factors and Free Radicals Meeting (FFFR), Kyoto (Japan),
December 2003. Does S-nitroso myoglobin regulate vascular tone? P.K. Witting.
(27)
Food factors and Free Radicals Meeting, Kyoto (Japan), December 2003. Is probucol a prodrug and 4,4’-dithiobis(2,6-di-tert-butyl)phenol the active intermediate that protects against
intimal hyperplasia? B.J. Wu, P.K. Witting, M. A. Raftery and R. Stocker.
(28)
* (invited oral presentation) Physicians Workshop (Concord Repatriation General Hospital),
June 2004.
Myoglobin-derived oxidative stress and the pathogenesis of myocardial
reperfusion injury. P.K. Witting
(29)
*
13th Meeting of the Society for Free Radical Research (Australasia), Christchurch, New
Zealand December 2004. Gpx-1 gene deletion results in decreased atherosclerosis associated
with increased oxidative stress and heme oxygenase-1 expression. B.S. Rayner, J.B. de Haan,
T. Sabaretnam, N. Stefanovic, C.L. Hawkins, Y-M Deng, J.J. Smolich, M.J. Davies, R. Stocker,
and P.K. Witting.
(30)
13th Meeting of the Society for Free Radical Research (Australasia), Christchurch, New
Zealand December 2004.
Effect of a phenolic antioxidant against neuronal cell apoptosis
induced by hypoxia/reperfusion. B.S. Rayner, D.T.T Duong, S.J. Myers, and P.K. Witting.
(31)
13th Meeting of the Society for Free Radical Research (Australasia), Christchurch, New
Zealand December 2004.
Tocopheryl succinate selectively inhibits proliferation of cancer
cells by disrupting the FGF autocrine loop: role of oxidative stress M. Stapelberg, N. Gellert,
P.K. Witting, M. Tomasetti, and J. Neuzil.
______________________________________________________
xxiv
______________________________________________________
(32)
13th Meeting of the Society for Free Radical Research (Australasia), Christchurch, New
Zealand December 2004.
Vitamin E analogues trigger apoptosis in HER2/erbB2-
overexpressing breast cancer cells by signaling via the mitochondrial pathway. X. Wang, P.K.
Witting, B.A. Salvatore, and J. Neuzil.
(33)
* (invited oral presentation) Australian Health and Medical Research Congress, Darling
Harbour Sydney, November 2004. Hydrogen peroxide promotes intracellular ion redistribution
in aortic endothelial cells: Elemental mapping by hard X-ray microprobe. P.K. Witting.
(34)
Hunter Cell Biology Meeting, Hunter Valley 2004. Mutations in the SPTLC1 protein, causing
hereditary sensory neuropathy type I, altered locaization of cytoskeletal and axonal proteins in
transfected, dorsal root ganglia cells. S.J. Myers, M. Kennerson, P.K. Witting, P.R. Robinson,
and G. Nicholson.
(35)
Cardiac Society of Australia and New Zealand, 2005. Serum amyloid A may contribute to the
hypercoaguable state in coronary artery disease. Y. Shen, C. Song, R. George, O. Akbar Ali,
P.K. Witting, C.L. Geczy and S.B. Freedman.
(36)
Cardiac Society of Australia and New Zealand, 2005. Serum amyloid A induces tissue factor
expression on a monocytic cell (THP-1) line. C. Song, R. George, P.K. Witting, C.L. Geczy and
S.B. Freedman.
(37)
Hunter Cell Biology meeting, 2005.
Mutations in the SPTLC1 protein causing hereditary
sensory neuropathy type 1 show altered localisation of cytoskeletal proteins in transiently
transfected SH-SY5Y cells. S.J. Myers, B. Marshan, A. Drew, M. Kennerson, P.K. Witting, and
G. Nicholson.
(38)
* (invited oral presentation) Australian Vascular Biology Society, Darling Harbour Sydney,
August 2004. Nitric oxide promotes myoglobin gene and protein expression in vascular smooth
muscle cells: a potential feed-back mechanism involved in vascular nitric oxide-homeostasis.
P.K. Witting.
(39)
* (invited oral presentation) The Heart Research Institute (Pyrmont Bridge Road, Sydney)
August 2004: Developing a cellular model for the testing of potential neuro-protective drugs to
combat Stroke. P.K. Witting.
(40)
* (invited oral presentation) 14th Meeting of the Society for Free Radical Research
(Australasia), Griffith University, Gold Coast, QLD December 2005. Nitric oxide promotes
myoglobin gene and protein expression in vascular smooth muscle cells: a potential feed-back
mechanism involved in vascular nitric oxide-homeostasis. P.K. Witting.
______________________________________________________
xxv
______________________________________________________
(41)
14th Meeting of the Society for Free Radical Research (Australasia and Japan), Griffith
University, Gold Coast, QLD December 2005. Gene regulation in differentiated neuronal cells
exposed to hypoxia-reoxygenation injury as a model for stroke. T.T.H. Duong, B.S. Rayner,
S.J. Myers, P.K. Witting.
(42)
14th Meeting of the Society for Free Radical Research (Australasia and Japan), Griffith
University, Gold Coast, QLD December 2005. Characterising a novel biomarker of myocardial
inflammation. N.A. Ellis, M.J. Raftery, and P.K. Witting.
(43)
14th Meeting of the Society for Free Radical Research (Australasia and Japan), Griffith
University, Gold Coast, QLD December 2005. Oxidant stress and damage in post-ischemic
mouse hearts: Specific effects of adenosine. B. Hack, P.K. Witting, B.S. Rayner, R. Stocker
and J.P. Headrick.
(44)
Cardiac Society of Australia and New Zealand, Canberra, 2006. Acute activation of systemic T
cells during plaque instability is associated with increased net plasma MMP-9 activity. A.Y.
Tiong, C. Song, P.K. Witting, S.B. Freedman, and D. Brieger.
(45)
Burn Unit Concord Repatriation General Hospital – Clinical Staff Meeting (July, 2006). S.N.
Parry, Z. Li, and P.K. Witting. Role for pro-oxidant myoglobin in promoting kidney dysfunction
in burns patients.
(46)
Australian and New Zealand Burns Association, Hobart, Tasmania 2006. Myoglobin promotes
oxidative stress in cultured kidney cells. S.N. Parry, P.K. Witting, P. Maitz, D. Milliss and Z. Li.
(47)
* (invited oral presentation) School of Medical Sciences, Griffith University (Gold Coast),
August 2006. Antioxidants as inhibitors of ischemia reperfusion injury to the heart or brain.
P.K. Witting.
(48)
* (invited oral presentation) The Heart Research Institute (Pyrmont Bridge Road, Sydney),
October 2006: Overview of research at in the Vascular Biology Group ANZAC Research
Institute. P.K. Witting.
(49)
5th Biennial Research Conference “From cell to Society” Health Sciences Faculty University of
Sydney. Leura, November 2006. Cellular and animal models for stroke. P.K. Witting.
(50)
* (invited oral presentation) 15th Meeting of the Society for Free Radical Research
(Australasia), University of Western Australia, Perth, WA December 2006. Characterising a
bio-marker for myopcardial inflammation. N. Ellis and, P.K. Witting.
(51)
(Prize winning oral presentation) 15th Meeting of the Society for Free Radical Research
(Australasia), University of Western Australia, Perth, WA December 2006. Use of synchrotron
radiation to measure changes to elemental ions, protein and lipid in cardiac ischemia
reperfusion injury. B.S. Rayner, and P.K. Witting.
______________________________________________________
xxvi
______________________________________________________
(52)
* (invited oral presentation) 15th Meeting of the Society for Free Radical Research
(Australasia), University of Western Australia, Perth, WA December 2006. Expression of wildtype and Y103F variant human Mbs in H9c2 cardiac cells enhances toxicity toward added
hydrogen peroxide P.K. Witting.
(53)
15th Meeting of the Society for Free Radical Research (Australasia), University of Western
Australia, Perth, WA December 2006. Myoglobin promotes oxidative stress in cultured kidney
cells. S.N. Parry, and P.K. Witting.
(54)
* 13th World Congress on Heart Disease (International Academy of Cardiology Annual
Scientific Sessions), Vancouver, BC, Canada, 2007. A synthetic polyphenol limits hydrogen
peroxide-induced cell death in H9c2 myocyte-like cells. B.S. Rayner and P.K. Witting
(55)
* (invited oral presentation) 10th International Sleep and Breathing Meeting, Palm Cove, QLD
2007. Obstructive sleep apnea, oxidative stress and vascular dysfunction. P.K. Witting
(56)
* (invited oral presentation) 5th International World Sleep Meeting, Cairns QLD 2007. Cell and
molecular mechanisms of atherosclerosis. P.K. Witting
(57)
(Prize winning poster presentation) Annual Meeting of the Australian Atherosclerosis
Society, Fremantle WA 2007. Neuroglobin over-expression in neuronal cells protects against
hydrogen peroxide insult. S. Antao and P.K. Witting
(58)
Annual Meeting of the Australian Atherosclerosis Society, Fremantle WA 2007. Characterizing
a novel biomarker of myocardial inflammation A. Szuchman-Sapir, D. Pattison, N. Ellis, C.
Hawkins, M.J. Davies, and P.K. Witting
(59)
* (invited oral presentation) 4th Meeting of the Society for Free Radical Research (Australasia
and Japan), Kyoto University, Kyoto, Japan December 2007. Neuroglobin over-expression in
neuronal cells protects against hydrogen peroxide insult. S. Antao and P.K. Witting
______________________________________________________
xxvii
______________________________________________________
Thesis Marking responsibility
Candidate
Ms Hong Duong
Ms Anna Mariana
Ms Kylie Vernardos
Thesis Title
Developing novel antioxidants as neuroprotective agents
Arsenic agents as anti-cancer drugs
Myocardial antioxidant enzyme systems,
ischemia reperfusion injury and selenium
Formation and reactions
Ms Vanessa Agon
of histidine peroxides generated by
photosensitized oxidation
Ms
andra
Yinbing Misincorporation of L-Dopa into cellular
Wang
proteins by neuronal cells
Ms Sarah Parry
Investigating the Toxic Effects of
Myoglobin on Renal Cells in Burns
Patients
Omar Akram
Aromatase and its role in testosterone
anti-atherogenic effects
Ms Meng-Choo Leck
Cellular Antioxidant activity of bilirubin
and biliverdin
Ms Min-Li Huang
Characterising the cell biology of
Charcot-Marie-Tooth neuropathy type 2A
Shane Antao
Neuroglobin Over Expression in Cultured
Neuronal
Cells
Protects
Against
Hydrogen Peroxide Insult
Ms Hui-Wen Yen
Regulations of phospholipase A2 in
human prostate cancer
Ms Christine Wong
Macrophage Secreted apolipoprotein E
and Fc receptors
Hitesh Peshavarariya
Mechanisms of cytoprotection from
oxidative stress in endothelial cells
Institution/Year
Honours in Pathology, The
University of Sydney, 2005
Honours
in
Biological
Sciences, The University of
Wollongong, 2006
PhD, Griffith University, 2005
PhD, Heart Research Institute,
2006
Honours in Pathology, The
University of Sydney, 2006
Honours in Pathology, The
University of Sydney, 2006
Honours in Pathology, The
University of Sydney, 2006
Honours in Pathology, The
University of Sydney, 2007
Honours in Pathology, The
University of Sydney 2007
Honours in Pathology, The
University of Sydney, 2007
Master of Medicine, The
University of Sydney, 2007
Honours in Medical Science,
UNSW, 2008
PhD, University of Melbourne,
2008
______________________________________________________
xxviii
______________________________________________________
Undergraduate and postgraduate students supervised by Witting
Candidate
Student status
University/Year(s)
Mr Ben Rayner
NHF funded PhD Scholarship (Faculty of
Medicine)
USyd/2005-2008
Ms Hong Duong
NHF funded Vacation student
Honours Program (Pathology)
Phillip Bushell Foundation funded PhD
(Faculty of Medicine)
USyd/2004
USyd/2005
USyd/2006-2009
Ms Sarah Parry
Honours (Cell Pathology)
USyd/2006
Mr Shane Antao
USyd Medical Faculty Vacation student
Honours Program (Cell Pathology)
PhD (Faculty of Medicine)
USyd/2005 and 2006
USyd/2007
USyd/2008
Ms Marzy Niknami
International Scholarship funded PhD
(Faculty of Medicine)
USyd/2006-2009
Ms Ying Sheng
Masters in Science (Faculty of Medicine)
USyd/2004-2005
Ms Anu Shanu
Masters in Biomedical Science (Faculty of
Science)
USyd/2006-2007
Mr Robert George
Medical Faculty Vacation Scholarship
USyd/2004
Mr Phillip Romo
Medical Faculty Vacation Scholarship
USyd/2004
Sandra Wang
Medical Faculty Vacation Scholarship
USyd/2005
Elicia Rodas
Medical Faculty Vacation Scholarship
USyd/2007
Ms Sarah Woods
Honours Program (Pathology)
USyd/2008
______________________________________________________